Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 5/20 | 0.71 |
| ▸ | EIF2AK3 | Q9NZJ5 | 3/20 | 0.71 |
| ▸ | PIM1 | P11309 | 1/20 | 0.55 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.55 |
| ▸ | IGF1R | P08069 | 9/20 | 0.49 |
| ▸ | PTK2 | Q05397 | 5/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | PLK1 | P53350 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL525791 | 1.00 | TTK (0.71) | TTKEIF2AK3PIM1PIM2IGF1R | |
| SCHEMBL526621 | 0.91 | TTK (0.85) | TTKEIF2AK3PIM1PIM2IGF1R | |
| SCHEMBL525543 | 0.90 | TTK (0.74) | TTKEIF2AK3PIM1PIM2IGF1R | |
| SCHEMBL525542 | 0.90 | TTK (0.74) | TTKEIF2AK3PIM1PIM2IGF1R | |
| SCHEMBL526751 | 0.90 | TTK (0.69) | TTKEIF2AK3PIM1PIM2IGF1R | |
| SCHEMBL14990362 | 0.90 | TTK (0.69) | TTKEIF2AK3PIM1PIM2IGF1R | |
| SCHEMBL10092921 | 0.90 | TTK (0.70) | TTKEIF2AK3PIM1PIM2IGF1R | |
| SCHEMBL14990366 | 0.83 | TTK (0.83) | TTKEIF2AK3IGF1RPTK2AURKA | |
| SCHEMBL14990540 | 0.83 | TTK (1.00) | TTKEIF2AK3PIM1PIM2IGF1R | |
| SCHEMBL526356 | 0.83 | TTK (1.00) | TTKEIF2AK3PIM1PIM2IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130143896-A1 | ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143896-A1 | ISOXAZOLO-QUINAZOLINES AS MODULATORS OF PROTEIN KINASE ACTIVITY | CSNK1A1, RPS6KA1, CSNK2A1 | TTK 341/4885EIF2AK3 315/4885PIM1 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.